Log in
NASDAQ:VKTX

Viking Therapeutics Price Target, Predictions & Analyst Ratings

$5.82
-0.11 (-1.85 %)
(As of 09/30/2020 12:00 AM ET)
Add
Compare
Today's Range
$5.80
Now: $5.82
$5.99
50-Day Range
$5.73
MA: $6.77
$8.11
52-Week Range
$3.26
Now: $5.82
$8.87
Volume1.18 million shs
Average Volume1.43 million shs
Market Capitalization$423.45 million
P/E RatioN/A
Dividend YieldN/A
Beta2

Analyst Ratings

Viking Therapeutics (NASDAQ:VKTX) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
11 Wall Street analysts have issued ratings and price targets for Viking Therapeutics in the last 12 months. Their average twelve-month price target is $16.33, predicting that the stock has a possible upside of 180.64%. The high price target for VKTX is $25.00 and the low price target for VKTX is $12.00. There are currently 11 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
VKTX Consensus Rating: BuyBuyBuyBuy
VKTX Consensus Rating Score: 3.003.003.083.00
VKTX Analyst Ratings: 0 Sell Rating(s)
0 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
12 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
VKTX Consensus Price Target: $16.33$16.00$14.50$14.33
VKTX Price Target Upside: 180.64% upside139.16% upside103.37% upside227.25% upside

Viking Therapeutics (NASDAQ:VKTX) Consensus Price Target History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Viking Therapeutics (NASDAQ:VKTX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/11/2020William BlairReiterated RatingBuyLow
9/10/2020B. RileyReiterated RatingBuy$15.00High
9/1/2020BTIG ResearchBoost Price TargetBuy$9.00 ➝ $12.00High
8/31/2020Chardan CapitalBoost Price TargetBuy$15.00 ➝ $20.00Medium
8/28/2020HC WainwrightBoost Price TargetBuy$18.00 ➝ $21.00High
8/6/2020Raymond JamesReiterated RatingBuy$25.00Medium
7/29/2020OppenheimerReiterated RatingBuy$12.00High
7/29/2020Stifel NicolausReiterated RatingBuy$14.00High
6/4/2020BMO Capital MarketsInitiated CoverageOutperform$14.00Medium
5/2/2020Maxim GroupInitiated CoverageBuy$14.00High
1/2/2020SVB LeerinkReiterated RatingOutperformMedium
7/16/2019CIBCInitiated CoverageOutperform ➝ Outperform$12.00Low
7/15/2019CitigroupInitiated CoverageOutperformHigh
11/9/2018Roth CapitalSet Price TargetBuy$23.00Medium
9/19/2018SunTrust BanksBoost Price TargetBuy$28.00High
6/1/2018LaidlawBoost Price TargetBuy$10.00 ➝ $15.00High
(Data available from 10/1/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)
This page was last updated on 10/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.